Circulating miRNAs (135a-5p, 646 AND 1271-5P) in breast cancer diagnosis and staging: integrative network and functional analysis
Open Access
- 26 January 2026
- journal article
- Published by Aboutscience Srl in Journal of Circulating Biomarkers
- Vol. 15 (1) , 47-57
Abstract
Introduction: Breast cancer (BC) remains a leading cause of cancer-related mortality among women worldwide.Despite advances in molecular diagnostics, reliable non-invasive biomarkers for early detection and disease staging remain limited. Circulating microRNAs (miRNAs) are promising epigenetic regulators involved in tumor development and progression.Methods: Determination of plasma miRNA (1271-5p, miR-646, and miR-135a-5p) differential expression profiles in an Egyptian cohort comprising 111 BC patients (stages 0–IV), 25 benign breast disease cases, and 24 healthy controls. Their diagnostic and stage-specific performance was assessed alongside integrative analyses of predicted and validated biological targets with network construction.Results: miR-1271-5p was downregulated in benign tumors but overexpressed across all BC stages. miR-646 was generally downregulated, with a notable increase in stage III, whereas miR-135a-5p was elevated in benign and early-stage disease before declining in metastatic stage IV. ROC analyses demonstrated strong discriminatory performance, with miR-1271-5p distinguishing early-stage BC from controls and benign lesions, miR-646 separating benign/early malignant cases from controls, and miR-135a-5p identifying metastatic disease. Combined miRNA panels improved discrimination between malignant and non-malignant samples and between early and advanced stages. Integrative analyses identified putative regulation of ZEB1, CCND2, FOXN3, and RUNX2, while TP53TG1, ZFAS1, XIST, and MALAT1 emerged as potential interaction hubs. Functional enrichment suggested involvement in AMPK, FOXO, SUMOylation, TP53-mediated, and immune-related pathways.Conclusions: Circulating miR-1271-5p, miR-646, and miR-135a-5p, individually and in combination, show promise as non-invasive diagnostic and stage-specific biomarkers for BC. Integrative network analyses provide insight into their putative roles in BC progression.Keywords
This publication has 39 references indexed in Scilit:
- Improving the Diagnosis and Follow‐Up of Chronic Myeloid Leukemia Using Conventional and Molecular TechniquesJournal of Clinical Laboratory Analysis, 2025
- Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitroMolecular and Cellular Biochemistry, 2022
- SRD5A3‐CDG:3Dstructure modeling, clinical spectrum, andcomputer‐baseddysmorphic facial recognitionAmerican Journal of Medical Genetics Part A, 2021
- LncRNA ZFAS1/miR-1271-5p/HK2 Promotes Glioma Development Through Regulating Proliferation, Migration, Invasion and ApoptosisNeurochemical Research, 2020
- Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axisJournal of Cancer Research and Clinical Oncology, 2020
- Analysis of p.Gly12Valfs*2, p.Trp24* and p.Trp77Arg mutations in GJB2 and p.Arg81Gln variant in LRTOMT among non syndromic hearing loss Egyptian patients: implications for genetic diagnosisMolecular Biology Reports, 2019
- miR-135a-5p Functions as a Glioma Proliferation Suppressor by Targeting Tumor Necrosis Factor Receptor–Associated Factor 5 and Predicts Patients' PrognosisThe American Journal of Pathology, 2019
- Breast cancer neoplastic seeding in the setting of image-guided needle biopsies of the breastBreast Cancer Research and Treatment, 2017
- miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2)Tumor Biology, 2014
- Real-Time Quantitative PCRMethods, 2001